Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11224598 | OYSTER POINT PHARMA | Methods of increasing lacrimal proteins |
Oct, 2035
(12 years from now) | |
US10456396 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(12 years from now) | |
US9597284 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(12 years from now) | |
US9532944 | OYSTER POINT PHARMA | Methods of improving ocular discomfort |
Oct, 2035
(12 years from now) | |
US9504644 | OYSTER POINT PHARMA | Methods of increasing tear production |
Oct, 2035
(12 years from now) | |
US9504645 | OYSTER POINT PHARMA | Pharmaceutical formulations for treating ocular conditions |
Oct, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Oct 15, 2024 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION;NASAL
10
United States
3
China
2
Israel
2
Singapore
2
Australia
2
Japan
2
European Union
1
Portugal
1
Korea, Republic of
1
Malaysia
1
EA
1
Canada
1
Denmark
1
Philippines
1
Mexico
1
Spain
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic